Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $18.93 in the last session, up 4.88% from day before closing price of $18.05. In other words, the price has increased by $4.88 from its previous closing price. On the day, 1.63 million shares were traded. ARWR stock price reached its highest trading level at $19.19 during the session, while it also had its lowest trading level at $18.3.
Ratios:
We take a closer look at ARWR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.74 and its Current Ratio is at 6.74. In the meantime, Its Debt-to-Equity ratio is 4.59 whereas as Long-Term Debt/Eq ratio is at 4.56.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 06 ’25 when Hamilton James C sold 32,729 shares for $19.82 per share. The transaction valued at 648,824 led to the insider holds 272,122 shares of the business.
O’Brien Patrick sold 29,184 shares of ARWR for $578,539 on Jan 06 ’25. The COO and General Counsel now owns 535,201 shares after completing the transaction at $19.82 per share. On Jan 07 ’25, another insider, O’Brien Patrick, who serves as the COO and General Counsel of the company, sold 8,000 shares for $19.69 each. As a result, the insider received 157,520 and left with 527,201 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 2355535616 and an Enterprise Value of 2644916480. For the stock, the TTM Price-to-Sale (P/S) ratio is 663.53 while its Price-to-Book (P/B) ratio in mrq is 12.70. Its current Enterprise Value per Revenue stands at 134.615 whereas that against EBITDA is -4.992.
Stock Price History:
The Beta on a monthly basis for ARWR is 0.96, which has changed by -0.45566946 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $36.72, while it has fallen to a 52-week low of $17.05. The 50-Day Moving Average of the stock is -9.19%, while the 200-Day Moving Average is calculated to be -17.71%.
Shares Statistics:
According to the various share statistics, ARWR traded on average about 1.51M shares per day over the past 3-months and 1504640 shares per day over the past 10 days. A total of 124.38M shares are outstanding, with a floating share count of 115.84M. Insiders hold about 6.90% of the company’s shares, while institutions hold 76.46% stake in the company. Shares short for ARWR as of 1731628800 were 9445166 with a Short Ratio of 6.62, compared to 1728950400 on 9334910. Therefore, it implies a Short% of Shares Outstanding of 9445166 and a Short% of Float of 8.9099996.
